Buy Pirbuterol powder (38029-10-6) hplc≥98% – β-Agonist Wisepowder
Synonyms (RS)-2-(tert-Butylamino)-1-(6-hydroxymethyl-5-hydroxy-2-pyridyl)ethanol acetate salt, 6-(2-tert-Butylamino-1-hydroxyethyl)-2-hydroxymethylpyridin-3-ol acetate
Molecular Formula C12H20N2O3
Molecular Weight 240.303 g/mol
Melting Point >152°C
InChI Key VQDBNKDJNJQRDG-UHFFFAOYSA-N
Appearance White to Off-White
Half Life 2 hours.
Solubility DMSO (Slightly), Methanol (Slightly)
Storage Condition Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years).
Application Pirbuterol Acetate is used as a bronchodilator, administered through inhalation.
Testing Document Available
03 Pirbuterol (38029-10-6) General Description
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established.
The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3† ,5†-adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
04 Pirbuterol (38029-10-6) History
Pirbuterol (trade name Maxair) was patented in 1971 and came into medical use in 1983. It is a short-acting β2 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.
Pirbuterol, 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylaminoethyl)pyridine, is a new beta2 adrenergic agonist bronchodilator. Comparison of the relative potencies of pirbuterol, salbutamol and isoproterenol as relaxants of isolated guinea-pig tracheal muscle and as positive chronotropic agents in isolated guinea-pig atria indicate that the relative selectivity of pirbuterol for pulmonary as opposed to cardiac tissue is 9 times greater than that for salbutamol and some 1500 times greater than that for isoproterenol. Pirbuterol is effective by the oral, intravenous and inhalation routes of administration. In conscious guinea pigs, pirbuterol antagonizes both histamine- and acetylcholine-induced bronchoconstriction and “microshock” anaphylaxis; combinations of pirbuterol and theophylline cause additive effects against histamine-induced bronchoconstriction. In conscious dogs, the cardiovascular effects of pirbuterol are clearly distinguished from those of salbutamol, in that salbutamol causes a more pronounced tachycardia. In anesthetized dogs the cardiovascular effects of pirbuterol and salbutamol are comparable; they are less potent than isoproterenol and have less pronounced although longer lasting effects.